TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1434656

Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy (THE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Transthoracic esophagectomy (TTE)
Number of subjects: 55
Study: 3908504

Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 43
Study: 31864068

Group type: EXPERIMENTAL
Intervention: Bifrontal tDCS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study: 30275528

Group type: EXPERIMENTAL
Intervention: S-HAM (dose-dense induction)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Standard double induction (TAD-HAM or HAM)
Number of subjects: 387
Study: 27586232

Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium (Mg)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 25188444

Group type: EXPERIMENTAL
Intervention: Noninvasive fibrosis score (NFS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: APRI
Number of subjects: 104

Group type: COMPARATOR
Intervention: FIB4
Number of subjects: 104

Group type: COMPARATOR
Intervention: Forns
Number of subjects: 104
Study: 22610193

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (80-110 mg/dL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Loose glycemic control (120-150 mg/dL)
Number of subjects: 13
Study: 20406576

Group type: EXPERIMENTAL
Intervention: Dietary intervention (gluten- and casein-free diet)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-diet control group
Number of subjects: 72
Study: 18566179

Group type: EXPERIMENTAL
Intervention: Peripheral Cutting Balloon Angioplasty (PCBA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (CBA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PCBA
Number of subjects: 40

Group type: COMPARATOR
Intervention: CBA
Number of subjects: 40
Study: 16011610

Group type: EXPERIMENTAL
Intervention: Aphtheal (5% amlexanox paste) during prodromal stage of RAU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aphtheal (5% amlexanox paste) after ulcer development
Number of subjects: 0
Study: 12448895

Group type: EXPERIMENTAL
Intervention: Porter/Brown scavenger system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accutron scavenger system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matrx scavenger system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 0
Study: 10898119

Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8653874

Group type: EXPERIMENTAL
Intervention: L-carnitine (500 mg IV as a single bolus)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1558796

Group type: EXPERIMENTAL
Intervention: Early postoperative chemotherapy including mitomycin C (MMC), OK‐432, UFT, PSK, and 5‐fluorouracil (5‐FU) bolus injections for 5 days starting on postoperative day 2
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group receiving therapy with MMC, OK‐432, UFT, PSK without 5‐FU
Number of subjects: 162
Study: 4026911

Group type: EXPERIMENTAL
Intervention: Azlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Both azlocillin and mezlocillin (4 g, intravenous infusion)
Number of subjects: 3
Study: 31859723

Group type: EXPERIMENTAL
Intervention: Bacterial cellulose biopolymer film and gel dressing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Essential fatty acids (Control)
Number of subjects: 24
Study: 30408642

Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS (c-tDCS2mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS or 1 mA tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: c-tDCS2mA over a control site
Number of subjects: 0
Study: 27378086

Group type: EXPERIMENTAL
Intervention: CHOP-O (CHOP with ofatumumab)
Number of subjects: 43
Study: 25757446

Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac
Number of subjects: 144

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 144
Study: 23691702

Group type: EXPERIMENTAL
Intervention: Pasteurized whole milk
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: UHT whole milk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diluted iodine contrast
Number of subjects: 60
Study: 19952806

Group type: EXPERIMENTAL
Intervention: Brisk walking (60 min at 7.0 ± 0.1 km/h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (resting for 8 hours)
Number of subjects: 14
Study: 18799996

Group type: EXPERIMENTAL
Intervention: Caffeine performance bar (CAF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isocaloric noncaffeine performance bar (CHO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo beverage (BEV)
Number of subjects: 24
Study: 16015255

Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinol (vitamin A)
Number of subjects: 1845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1845
Study: 12551869

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (5 categories: no alcohol or <1 drink monthly, 1 to 3 drinks monthly, 1 to 4 drinks weekly, 5 to 7 drinks weekly, > or =2 drinks daily)
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 2833
Study: 11783211

Group type: EXPERIMENTAL
Intervention: Longhu Xingnao Granule (LHXNG) after light puncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 50
Study: 10155675

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine plus metoclopramide
Number of subjects: 0
Study: 1842215

Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Azapropazone 300 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Azapropazone 600 mg
Number of subjects: 80
Study: 6786129

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (SCG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate (SCG)
Number of subjects: 0
Study: 31452425

Group type: EXPERIMENTAL
Intervention: FESS combined with PNN
Number of subjects: 85

Group type: COMPARATOR
Intervention: FESS alone
Number of subjects: 85
Study: 28550963

Group type: EXPERIMENTAL
Intervention: Educational video and prompt list intervention
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 259
Study: 25885285

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (monotherapy)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (combination therapy)
Number of subjects: 289
Study: 23746110

Group type: EXPERIMENTAL
Intervention: Heat therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 21466743

Group type: EXPERIMENTAL
Intervention: Full conditions (after consuming breakfast)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hungry conditions (after an overnight fast)
Number of subjects: 27

Group type: COMPARATOR
Intervention: All foods except banana
Number of subjects: 27
Study: 18619804

Group type: EXPERIMENTAL
Intervention: Quality of Life in Reflux and Dyspepsia food/drink problems
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Quality of Life in Reflux and Dyspepsia vitality
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD workdays with reflux symptoms
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Symptoms of heartburn
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Symptoms of acid reflux
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Global rating of change in stomach problems
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD hours absent at work
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD reduced productivity at work
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD reduced productivity during other activities
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Emotional global rating of change
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Feeling thermometer
Number of subjects: 217
Study: 17497439

Group type: EXPERIMENTAL
Intervention: Heparin plus 1 ng/kg/min iloprost
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study: 15059371

Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 285
Study: 11486442

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9755350

Group type: EXPERIMENTAL
Intervention: Self-management program for inhaler medication compliance (6 weeks)
Number of subjects: 55
Study: 7663491

Group type: EXPERIMENTAL
Intervention: Steroid group (0.2 mg salbutamol plus 0.2 mg budesonide t.i.d.)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo group (0.2 mg salbutamol plus placebo t.i.d.)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Steroid group follow-up (28-36 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cessation group (decrease and stop corticosteroid after 2 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Continuous group (continued treatment)
Number of subjects: 116
Study: 2562087

Group type: EXPERIMENTAL
Intervention: pH adjusted 2% mepivacaine solution (pHAS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard 2% mepivacaine solution
Number of subjects: 200
Study: 368743

Group type: EXPERIMENTAL
Intervention: Progestogens (single oral doses)
Number of subjects: 0
Study: 31996920

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 3352015

Group type: COMPARATOR
Intervention: No Oseltamivir (Control)
Number of subjects: 3352015
Study: 31022403

Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg subcutaneously every 4 weeks)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard care (blood pressure control, sodium-restricted diet, antihypertensive agents)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 175
Study: 28669885

Group type: EXPERIMENTAL
Intervention: EA (primary activation of TEA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: LA (no intraoperative activation of TEA)
Number of subjects: 45
Study: 25419678

Group type: EXPERIMENTAL
Intervention: Natural α‐TOH supplementation (n=40)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Synthetic α‐TOH supplementation (n=33)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control without supplementation (n=36)
Number of subjects: 109
Study: 25013762

Group type: EXPERIMENTAL
Intervention: Telecare program with 24 hours of consultation services via a health communication center (Group 2)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Public health nurse consultation at outpatient clinic (Group 1)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 298
Study: 22994935

Group type: EXPERIMENTAL
Intervention: Vitamin E-stabilized highly cross-linked polyethylene cemented cup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cross-linked polyethylene cemented cup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 18413439

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -110 degrees C
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -60 degrees C
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local cold therapy between -20 degrees C and -30 degrees C
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -110 degrees C with glucocorticoids (GC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -60 degrees C with glucocorticoids (GC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local cold therapy with glucocorticoids (GC)
Number of subjects: 55
Study: 17331915

Group type: EXPERIMENTAL
Intervention: Personal emergency response systems (PERS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard ED discharge planning
Number of subjects: 86
Study: 15389223

Group type: EXPERIMENTAL
Intervention: Controlled phlebotomy for graded reduction of iron stores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11605924

Group type: EXPERIMENTAL
Intervention: Ambulatory epidural analgesia with ambulation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ambulatory epidural analgesia without ambulation
Number of subjects: 160
Study: 9806676

Group type: EXPERIMENTAL
Intervention: Underwater seal technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cuff inflated to a pressure of 25 cm H2O
Number of subjects: 20
Study: 7912948

Group type: EXPERIMENTAL
Intervention: Neostigmine 1.5 mg and atropine 0.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spontaneous recovery (Control)
Number of subjects: 80
Study: 2810159

Group type: EXPERIMENTAL
Intervention: Liver function tests performed on patients with confirmed cholecystitis (206/270)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Liver function tests performed on patients with other diagnoses (64/270)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Normal liver function tests in suspected cholecystitis
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Presence of ductal calculi in proven cases of cholecystitis
Number of subjects: 311
Study: 31395176

Group type: EXPERIMENTAL
Intervention: Preoperative virtual reality (VR) experience of 3D reconstructed MRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preoperative information about MRI (NR group)
Number of subjects: 0
Study: 29442459

Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Glasgow Prognostic Score (GPS)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MNA test
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: GPS
Number of subjects: 85
Study: 26169131

Group type: EXPERIMENTAL
Intervention: Helpful neighbors
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Unhelpful neighbors
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Living in U.S. Census tract with low educational achievement
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Living in Census tracts with high poverty
Number of subjects: 2295
Study: 24237357

Group type: EXPERIMENTAL
Intervention: Stabilisation splints (SS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Palatal splint (PS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline (no splint)
Number of subjects: 23
Study: 21997317

Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealer (BVS)
Number of subjects: 114
Study: 17933588

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 364

Group type: COMPARATOR
Intervention: Celecoxib 400 mg
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 16491317

Group type: COMPARATOR
Intervention: Cold face test (CFT) using three cold packs at 0.5 degrees C applied to the face.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold face test (CFT) in patients with baroreflex impairment.
Number of subjects: 12
Study: 12781313

Group type: EXPERIMENTAL
Intervention: Consultation‐Liaison Psychiatry (C‐L Psychiatry) intervention; early screening with systematic multidisciplinary management for emotional disorders.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 176
Study: 10940543

Group type: EXPERIMENTAL
Intervention: Pergolide 0.05 mg bid
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Pergolide 0.25 mg bid
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Pergolide (both doses)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 9314792

Group type: EXPERIMENTAL
Intervention: Condom availability program in New York City public high schools
Number of subjects: 12857

Group type: EXPERIMENTAL
Intervention: Higher-risk students in New York City (three or more sexual partners in the past 6 months)
Number of subjects: 12857

Group type: COMPARATOR
Intervention: Condom availability program
Number of subjects: 12857
Study: 7755466

Group type: EXPERIMENTAL
Intervention: ISIS tutorial program (interactive session with computer for 30 to 60 minutes)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual education (contacts with physicians, nurses, dieticians, health-oriented booklets)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: ISIS tutorial program (for patients with initial scores ≤ 16)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual education (for patients with initial scores ≤ 16)
Number of subjects: 158
Study: 3291787

Group type: EXPERIMENTAL
Intervention: Combined measles, mumps, and rubella vaccine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Single component measles vaccine
Number of subjects: 319
Study: 31313720

Group type: EXPERIMENTAL
Intervention: Nasal CPAP (SuperNO2VA) at 10 cmH2O, oxygen flow rate of 15 l/min
Number of subjects: 136

Group type: COMPARATOR
Intervention: Oxygen via nasal cannula at 5 l/min
Number of subjects: 136
Study: 28198722

Group type: EXPERIMENTAL
Intervention: Video testimonial (VM) included in survey
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Stand-alone Physician Orders for Life-Sustaining Treatment (POLST) and living will (LW) documents
Number of subjects: 1366
Study: 26164820

Group type: EXPERIMENTAL
Intervention: Metacognition (measured with the Metacognitive Assessment Scale‐Abbreviated)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Baseline negative symptoms (measured with the Positive and Negative Syndrome Scale)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neurocognition (measured with the MATRICS battery)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Affect recognition (measured with the Bell Lysaker Emotion Recognition Task)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Defeatist beliefs (measured with the Recovery Assessment Scale)
Number of subjects: 53
Study: 23556549

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV pre-treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard NAC regimen (20.25 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified NAC regimen (12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both NAC regimens
Number of subjects: 0
Study: 21534677

Group type: EXPERIMENTAL
Intervention: Motivational plus behavioral skills intervention
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Control group (comparison after-school program)
Number of subjects: 1563
Study: 19157102

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16941367

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 11241
Study: 14564262

Group type: EXPERIMENTAL
Intervention: Cancellous impaction autografting with a 10-mm humeral component
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard surgical technique without grafting
Number of subjects: 10
Study: 10839209

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea extract SHR-5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9337947

Group type: EXPERIMENTAL
Intervention: Brief cognitive therapy (BCT) plus 'treatment as usual'
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brief cognitive therapy (BCT)
Number of subjects: 48
Study: 8210821

Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclude non-adherers from analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer non-adherers to alternative treatment group at randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Censor non-adherers at time of treatment change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer non-adherers to alternative treatment group at time of treatment change
Number of subjects: 0
Study: 3320901

Group type: EXPERIMENTAL
Intervention: I.V. cefuroxime (1.5 g)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30132465

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 0
Study: 27008297

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 3 mL with 2.5 µg dexmedetomidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 3 mL with 5 µg dexmedetomidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 3 mL with 10 µg dexmedetomidine
Number of subjects: 90
Study: 25721889

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 0
Study: 23803871

Group type: EXPERIMENTAL
Intervention: Ketamine (0.54 mg/kg within 30 min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20107146

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for infants, 20 mg for older children) for 4 months
Number of subjects: 2482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study: 18382142

Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Td
Number of subjects: 0